Anixa Biosciences Inc (ANIX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$1.5M
Cash & Equivalents
$4.4M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$104M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT04674306 Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer PHASE1 Active Not Recruiting 35
NCT05316129 Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer PHASE1 Recruiting 10

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ANIX.

SEC EDGAR Filings

All SEC filings for Anixa Biosciences Inc on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.